The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

D Molecular Therapeutics said it is streamlining operations to offset expected expenses as it accelerates the timelines for its Phase III trials.

NEW YORK – Iksuda Therapeutics on Monday said it will expand an ongoing Phase I trial of the HER2-targeted antibody-drug conjugate (ADC) IKS014 in solid tumors to US sites. The Newcastle, ...

NEW YORK – Imagene AI on Tuesday said it closed a $23 million Series B financing round to advance its multi-modal digital pathology foundation models for precision medicine. Oracle Chairman and CTO ...

At a subsequent visit, the patient's maternal-fetal medicine doctor reviewed the NIPT result and wrote in consult notes that the laboratory didn't recommend retesting. The doctor also acknowledged in ...

NEW YORK – Adagene said on Tuesday that Sanofi has made a $25 million investment in the company to support a clinical trial of the anti-CTLA-4 agent muzastotug and exercised its option under their ...

NEW YORK – Rutgers New Jersey Medical School has rolled out blood testing for lipoprotein (a), a biomarker associated with cardiovascular disease risk, as part of routine care at another hospital site ...